1. Home
  2. R&D for Health Products

R&D for Health Products

Including in Emergencies and Neglected

Update on the mRNA Technology Transfer Programme
WHO’s mRNA Vaccine Hub Faces ‘Uncertainty and Structural Weaknesses’
The challenges of decentralising vaccine production to Africa
TB has reclaimed its place as the world’s biggest infectious killer – but are its days numbered?
WHO Updates List of Most Threatening Drug-Resistant Bacteria as Pharma Warns New Antibiotic Pipeline is Inadequate
Antibacterial innovation: parachutes needed
WHO target product profiles: four diagnostic tests needed in the effort to eliminate African trypanosomiasis
Building Africa's first mRNA vaccine facility
As pandemic raged, global south lacked vaccines. Never again, researchers vow.
A pandemic treaty for equitable global access to medical countermeasures: seven recommendations for sharing intellectual property, know-how and technology
Discussion Paper on IP and Access to Publicly Funded Research Results in Health Emergencies. Publicly Funded International R&D Projects
Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain
Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
Towards a reformed research and development ecosystem for infectious disease
Subscribe to R&D for Health Products